Home / Services / HIV Drug Resistance Testing (Clinical) / HIV Drug Resistance Testing (Clinical) / HIV Drug Resistance Testing (Clinical)
Sample type:
Plasma
Turn-around
10 working days
Service details
Please request a quote by clicking in the green box above and we will send you all of required documentation (i.e. request form, instructions for the request forms, instruction for the preparation of the patient, instructions for transportation of samples, etc.).
You can also fill the HIV-1 Drug Resistance test request form (KF87) which can be downloaded here (Request Form) and sent together with the samples.
HIV-1 drug resistance testing involves PCR amplification and sequencing of the protease (PR), reverse transcriptase (RT) and integrase (IN) genes of HIV, associated with protease, reverse transcriptase and integrase inhibitors, respectively.
Sample requirements and general information:
1. Sample types:
- Fresh plasma collected in a PPT tube / frozen plasma (at least 1000 ul)
2. Sample rejection criteria:
- Haemolysed, lipaemic samples
- Samples without any details / incomplete request forms
- Samples with insufficient volume
- Fresh samples >72 hours from collection
3. Request Form:
- The HIV-1 Drug Resistance test request form (KF87) can be downloaded here (Request Form) and sent together with the samples.
4. Sample transport:
- Fresh samples should be received on ice (2 - 8 °C in a cooler box)
- Frozen samples should be received on dry ice / frozen
5. Opening hours:
- Monday - Friday (8:00 to 16:30)
6. Service details:
See hardcopy
7. Factors known to significantly affect the test performance:
- Samples that have undergone >1 freeze / thaw cycle
- Samples with viral loads < 1000 RNA copies / ml
8. Clinical advice and report:
9. Customer survey and complaints:
- Please complete our customer satisfaction survey here
- If you have any complaints about our service, please contact the laboratory manager or laboratory director at our contact webpage.. The laboratory has a complaints procedure number KWI04 - Resolution of complaints - to follow and address your concerns.
10. Policy on protection of personal information
- All KRISP staff arerequired to sign a Confidentiality Statement (KF35) to maintain the confidentiality of pateint information and results.
- All intruments and access to resutls and patient data are password protected, and stored in access-controlled areas thereby restricitng unauthorized access. The KRISP policy on confidentiality is also guided bu the UKZN Policy on Research Ethics.
Category
HIV Drug Resistance Testing (Clinical)
Sub-category
HIV Drug Resistance Testing (Clinical)
KRISP has been created by the coordinated effort of the University of KwaZulu-Natal (UKZN), the Technology Innovation Agency (TIA) and the South African Medical Research Countil (SAMRC).
Location: K-RITH Tower Building
Nelson R Mandela School of Medicine, UKZN
719 Umbilo Road, Durban, South Africa.
Director: Prof. Tulio de Oliveira